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Abstract
Background: The neuropeptide S receptor (NPSR1) and its ligand neuropeptide S (NPS) have received increased attention in
the last few years, as both establish a previously unknown system of neuromodulation. Animal research studies have
suggested that NPS may be involved in arousal/wakefulness and may also have a crucial role in sleep regulation. The single
nucleotide polymorphism (SNP) rs324981 in NPSR1 has begun to shed light on a function of the NPS-system in human sleep
regulation. Due to an amino acid exchange, the T-allele leads to an increased sensitivity of the NPSR1. In the only genome-
wide association study to date on circadian sleep parameters in humans, an association was found between rs324981 and
regular bedtime. However, the sleep parameters in this study were only measured by self-rating. Therefore, our study aimed
to replicate these findings using an objective measure of sleep.
Methods: The study included n = 393 white subjects (62–79 years) who participated in an actigraphic assessment for
determining sleep duration, rest duration, sleep onset, rest onset and sleep onset latency. Genotyping of the SNP rs324981
was performed using the TaqMan OpenArray System.
Results: The genotype at rs324981 was not significantly associated with rest onset (bedtime) or sleep onset (p = .146 and
p = .199, respectively). However, the SNP showed a significant effect on sleep- and rest duration (p = .007 and p = .003,
respectively). Subjects that were homozygous for the minor T-allele had a significantly decreased sleep- and rest duration
compared to A-allele carriers.
Conclusion: The results of this study indicate that the sleep pattern in humans is influenced by the NPS-system. However,
the previously reported association between bedtime and rs324981 could not be confirmed. The current finding of
decreased sleep duration in T/T allele carriers is in accordance with studies in rodents reporting similar results after NPS
application.
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The neuropeptide S receptor (NPSR1) is a metabotropic G-
protein coupled receptor with seven transmembrane helices [1].
The receptor was first described in 2002 and was deorphanized in
2004 by the identification of neuropeptide S (NPS) as its ligand
[2,3]. NPS belongs to the neuropeptides, a diverse group of
neuronal expressed signalling molecules involved in a variety of
brain functions. Studies of rats have demonstrated that the
injection of NPS strongly induces wakefulness and reduces the
occurrence of all sleep stages [4,2].
NPS seems to be expressed in only a few defined regions (with
possibly wide-ranging neuronal projections), which supports the
notion of a neuromodulatory function of the NPS-system [5]. The
highest concentration of NPS precursor mRNA has been found in
brainstem neurons adjacent to the locus coeruleus, in the
parabrachial nucleus and in the principle sensory trigeminal
nucleus [2,4]. Both the locus coeruleus area and the parabrachial
nucleus are known for their contribution in the ascending arousal
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network, and the sensory trigeminal nucleus is also strongly
modulated by the sleep/wake cycle [6,7]. Compared to the NPS
expression pattern, the NPSR1 precursor mRNA is distributed
more widely in the brain. It covers important hubs of the sleep/
arousal system in the hypothalamus and thalamus, but is also
present in the cortex and the amygdala. In particular, it can be
found in hypothalamic regions, like the perifornical region and the
tuberomammilary nucleus, which are known for their expression
of the wake-promoting orexin and histamine respectively [8–10].
Moreover, NPSR1 mRNA has been found in the key regions
responsible for sleep induction.
On the molecular level, the receptor activates protein kinases
and increases the intracellular cAMP and Ca2+ level [2]. In this
way, NPS is thought to modulate the neurotransmission of the
NPSR1 expressing neurons.
Although the NPS-system seems to play a crucial role in sleep
modulation, most of the findings were derived from studies of
rodents, and limited data is available on its effect on sleep in
humans. The single nucleotide polymorphism rs324981 (lying at
triplet position 107 of the NPSR1 gene on chromosome 7p14.3),
provides the opportunity to non-invasively study the effect of
NPS/NPSR1 in humans. The T-allele of the SNP leads to an
amino acid exchange in the active centre of the receptor binding
site (Asn -. Ile). This causes approximately a tenfold increased
sensitivity to neuropeptide S [11]. The T-allele has already been
identified as a risk-factor for asthma and panic-disorder, the
symptomatology of which might be partially driven or worsened
by a pathologically altered arousal [12–14]. A genome wide
association study (GWA) by Gottlieb et al. [15], which investigated
the sleep-related parameter usual bedtime (the time a person goes
to bed) and sleep duration, found an association between rs324981
and bedtime. This study was able to show a delay of usual bedtime
in T-allele carriers. However, the sleep parameters in this study
were only measured subjectively, through two single questionnaire
items. Thus, our study aimed to replicate the influence of the
functional NPSR1 polymorphism on the sleep pattern via an
objective measure of sleep. Based on the findings of Gottlieb et al.
and the results from physiological studies, we hypothesized a delay




All subjects gave written informed consent to participate in the
study. The procedures were conducted according to the Decla-
ration of Helsinki and approved by the University of Leipzig’s
ethics committee (registration-number: 263-2009-14122009).
Subjects
Subjects were participants of the large-scale research project
‘LIFE’ (Leipzig Research Center for Civilisation Diseases). Within
LIFE, a population based cohort of adult persons (40–79 years)
was recruited in Leipzig (district), Germany. The subjects
underwent a deep phenotyping, including blood sampling. A
proportion of the elderly subjects (.60 years) also participated in
an actigraphic assessment. All subjects were systematically
screened for neurological conditions and medication use. More-
over, subjects were examined for psychiatric disorders using the
structured clinical interview (SKID-I).
Actigraphic sleep data and rs324981 SNP genotype data were
available in n = 436 elderly white subjects. Subjects with less than
5 days of actigraphic data were excluded from analysis (n = 14).
Additional subjects were excluded due to neurological or
psychiatric disorders or the use of psychotropic drugs (n = 29). In
detail, exclusion criteria comprised current anxiety disorders
(panic disorder, generalized anxiety disorder, posttraumatic stress
disorder, obsessive–compulsive disorder, social phobia, specific
phobia), current affective disorders (major depression, bipolar
disorder, mania, dysthymia, cyclothymia), psychotic disorders (e.g.
schizophrenia) and major neurological conditions (Parkinson’s
disease, multiple sclerosis, stroke and epilepsy). Exclusion criteria
further comprised psychotropic drugs, such as antidepressants,
neuroleptics, benzodiazepines and z-hypnotics. The remaining
393 subjects (females = 175), aged between 62 and 79 years
(mean: 70.5 years; SD: 3.6 years), were suitable for analysis.
Genotyping
Genomic DNA was extracted from EDTA treated blood
samples using the Autopure LS instrument (Qiagen, Hilden).
Genotyping of SNP rs324981 was performed using TaqMan SNP
Genotyping Assays on OpenArray-Chips (Applied Biosystems;
Foster City, California). The call rate was 99.7% and the allele
frequency was within the Hardy-Weinberg equilibrium (HWE;
minor allele frequency = 47%; pHWE = 0.45). Genotyping was
performed in the Institute of Laboratory Medicine, Universität
Leipzig.
Actigraphy
For objectively determining parameters of sleep, the activity of
the subjects was measured using the SenseWear Pro 3 actigraph
(BodyMedia; Pittsburgh, Pennsylvania). It was attached to the
upper right arm, recording data about 2-axis body acceleration,
skin temperature, heat flux and galvanic skin response. Based on
these sensory parameters, the Sensewear algorithm identified
periods of sleep or rest. Validation studies have shown that the
Sensewear actigraph accurately detects sleep, as compared to the
‘‘gold standard‘‘ polysomnography [16]. Subjects of the analysis
sample wore the actigraph for an average of 6.3 days (range: 5–7
days), with the recording interval set to 1 minute. The wearing and
removal of the actigraph was detected by an off-body detection.
Days were defined as the 24 h interval from 12:00 pm (mid-day) to
11:59 am of the following day, thus covering the night sleep
interval completely. Only days with a wearing time of at least
1200 min (20 h), and without gaps in the relevant night sleep time
window were included in the study. For each subject, actigraphy
raw data was processed in a separate file, based on a custom Excel
template with Visual Basic for Applications (VBA) macros
(Microsoft; Redmond), which computed all sleep variables
automatically. To differentiate between night sleep and day sleep,
the respective sleep intervals were tagged, referring to the time of
day and a sleep diary that was kept by the subjects in parallel with
the actigraphic assessment. The current study only focused on
sleep that occurred at night time. The observed sleep variables
comprised of the following: beginning of sleep (sleep onset),
bedtime (rest onset), the time period subjects were at sleep (sleep
duration), the time period subjects stayed in bed (rest duration) and
the time it took subjects to fall asleep (sleep onset latency). Sleep
onset latency was defined as the rest interval prior to sleep onset
that was not interrupted by more than 1 min of activity. Rest onset
was defined as the beginning of this rest interval.
Statistical Analysis
Statistical analysis was performed with SPSS Statistics 21 (2012;
IBM corp.; Armonk, New York). The sleep parameters used for
analysis were calculated as the individual means across all nights
matching the above criteria. Different genetic inheritance models
were tested for their suitability to the data by using the Akaike
Sleep and the Neuropeptide S Receptor Gene
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information criterion (AIC) [17,18]. Based on the lowest mean
AIC score, the T-recessive model was identified as providing the
best fit of all models (co-dominant or additive, dominant, recessive,
and over-dominant). For testing the genetic association between
the rs324981 genotype and sleep, a Multivariate Analysis of
Covariance (MANCOVA) was conducted. The five sleep pheno-
types mentioned above served as multivariate endpoints of our
analyses. Sex, age and body mass index (BMI) were included as
covariates, as these factors have shown to affect the sleep pattern
[19,20]. Univariate follow-up tests were conducted separately for
each sleep parameter. In all univariate analyses, the alpha-level
was corrected for multiple testing by using Bonferroni’s method.
All statistical tests were two-sided. The sleep variables were
normally distributed (Kolmogorov-Smirnov-Test; p.0.05), except
for sleep onset latency which had a lognormal-like distribution
[21,22]. Therefore, an inverse hyperbolic sine (IHS) transforma-
tion was applied on sleep onset latency before statistical analysis.
The IHS transformation is similar to a log transformation, but
defined at zero [23]. For improving the interpretability, mean
values and confidence intervals (CI) were back-transformed after
analysis.
Results
We first investigated the influence of covariates on the sleep
parameters. We observed significant effects for sex (p = .009) and
BMI (p,.001) on sleep duration (with shorter duration in men and
in subjects with higher BMI). BMI was furthermore associated
with rest duration (p = .001), sleep onset (p = .002), rest onset
(p = .015) and sleep onset latency (p,.001).
Multivariate analysis showed a significant association between
the NPSR1 genotype at rs324981 and sleep, as assessed with all five
sleep-related parameters (F(5, 384) = 2.262, p = .048, gp
2 = .029).
This effect was mainly due to the significant impact on sleep
duration (F(1, 388) = 7.400, p = .007, gp
2 = .019) and rest duration
(F(1, 388) = 8.853, p = .003, gp
2 = .022). Sleep- as well as rest-
duration were shorter in individuals with the homozygote T/T
genotype, than in A-allele carriers. When separated for sex the
same trend was seen in both females and males. In accordance
with this, we found no significant interaction between sex and
genotype (sex x genotype: sleep duration, F(1, 387) = .198, p = .656;
rest duration, F(1, 387) = .028, p = .868).
Sleep onset, rest onset, and sleep onset latency were
not significantly associated with the SNP genotype at rs324981
(F(1, 388) = 1.654, p = .199, gp
2 = .004, F(1, 388) = 2.127, p = .146,
gp
2 = .005 and F(1, 388) = 1.698, p = .193, gp
2 = .004, respectively;
Table 1). None of these effects interacted with sex, age or BMI.
Discussion
The current study illustrates evidence for an association
between NPSR1 and objectively obtained sleep parameters in
humans. The functional SNP rs324981, located in the gene
encoding NPSR1, was found to have a significant effect on sleep
duration and rest duration in a sample of elderly subjects. Subjects
with the homozygous T/T genotype had a significantly shorter
sleep- and rest duration compared to subjects carrying the A-allele.
These findings partially confirm the GWA study by Gottlieb et al.
[15] in terms of a general association between rs324981 and sleep-
related traits in humans. However, the current study was not able
to replicate an effect of the rs324981 genotype upon rest onset
(bedtime). Even though we also observed a later rest onset in
homozygous T-allele carriers in the current sample, this effect
failed to reach statistical significance.
A possible explanation for this discrepancy may be accounted
for by the difference between the methodical approaches.
Measuring sleep by actigraphy is far more objective than the
traditional assessment by questionnaire. In fact, there is only a
moderate correlation between self-reported and objectively
measured sleep duration [24]. Subjective assessment is consistently
found to be an overestimation of sleep duration and sleep onset
[25,26]. Moreover, the study by Gottlieb et al. [15] used only a
single question asking for usual bedtime/sleep duration, and did
not collect data about multiple nights. The higher mean age of the
current sample (D 14.7 years) might also partially explain the
differing results. Most of the subjects were in retirement age, which
is advantageous in that job engagement is not inhibiting or
influencing sleep preferences. However, since circadian sleep
habits change with increasing age [27], the respective genetic
associations might be less pronounced in the elderly. In the age
range of the current sample we observed no influence of age on
any sleep parameter. Although the present study provides a more
objective measure of bedtime, the sample size was smaller than in
the study by Gottlieb et al. (n = 393 vs. n = 738). Therefore we
cannot rule out that the association was too weak to be detected
with the available statistical power.
Our finding of an association between rs324981 and sleep
duration is consistent with studies in rats, reporting that direct
application of NPS into the brain, strongly influences the sleep
architecture. In the study by Xu et al. [2], rats spent significantly
more time in wakefulness, compared to rapid eye movement sleep
(REM), as well as slow wave sleep (SWS) phases I and II, which
were shortened during the first hour after NPS application. Similar
results were found by Zhao et al. [4], who reported decreased sleep
phases and increased high frequency power in the sleep EEG.
These studies indicate that NPS can inhibit both REM and non-
REM sleep phases, which are thought to be regulated by partially
independent systems [28]. Since the T-allele increases the
sensitivity of NPSR1 towards NPS, the current finding of a
shorter mean sleep duration in T/T carriers, is in line with the
expectations. The causal relationship however, might be far more
complicated since it is not known how the rs324981 polymorphism
acts during ontogenesis. It has been hypothesised that gain-/loss-
of-function alleles may induce compensatory mechanisms or
interact with other unknown genetic/environmental factors [29–
31].
The functional mechanism underlying the effect of NPS/
NPSR1 on sleep and arousal is not well understood. Generally,
sleep and wakefulness are thought to be regulated by at least two
antagonizing brain systems; the arousal- and the sleep-promoting
system. The arousal system mainly originates in the brainstem and
in the lateral hypothalamus, innervating the forebrain and the
cortex, where the system is thought to modulate cortical activity
[32]. Strong NPSR1 mRNA expression was detected in the lateral
hypothalamus, including orexinergic neurons in the perifornical
region as well as the histaminergic tuberomammilary nucleus [9].
A recent study was able to show that NPS application enhances
the hypothalamic expression of c-Fos (an indirect marker of
neuronal activity) in the respective histaminergic and orexinergic
regions [4]. It was therefore proposed that the arousal-promoting
effect of NPS is partially mediated by the release of histamine and
orexin. Histaminergic neurons have widespread projections and
normally show high activity during wakefulness, and are inactive
during sleep [28]. Pharmacological interventions with histamine
receptor agonists/antagonists have repeatedly demonstrated the
influence of histamine on the wake/sleep cycle [33]. Orexin is,
similar to NPS, a neuropeptide with a wake-promoting effect [8].
Loss of the orexinergic neurons is known to be a cause of
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narcolepsy [34]. NPSR1 mRNA is also present in brain regions,
which are assigned to the sleep-promoting system; the lateral
preoptic area, the ventrolateral preoptic nucleus and the nucleus of
the horizontal limb of the diagonal band [9]. Whether NPSR1 has
an inhibiting effect in these neurons remains to be investigated. In
vivo, NPS might be co-released from the brainstem neurons of the
ascending arousal sytem (i.e. potentially from neurons near the
locus coeruleus and the parabrachial nucleus) [9,4]. Immunohis-
tochemical analyses indicate that NPS-immunopositive neurons
directly project to NPSR1 expressing neurons in the hypothalamus
[35]. In this way, NPS might modify the effect of the regular
neurotransmitters on arousal-promoting or sleep-inhibiting neu-
rons [9].
The findings of the current study might have positive
implications for the continuing research into the molecular
genetics of sleep. This is not only important for developing new
treatments for sleep problems, but also for understanding the
comorbidity of sleep and psychiatric conditions, as sleep and
arousal are strongly linked to the pathophysiology and treatment
of disorders such as affective disorders and attention deficit
hyperactivity disorder [36–39].
Conclusions
The functional SNP rs324981 located in the gene of NPSR1
was significantly associated with objectively obtained sleep
parameters in a sample of elderly white subjects. Although, the
previous finding of an effect on self-reported bedtime could not be
confirmed by using actigraphy, the findings still point to a role of
the NPS system in human sleep. As sleep has a high association
with well-being, cognitive abilities as well as psychological and
physical health, this study emphasizes the need for more research
to determine the specific function of NPS/NPSR1 in the human
brain.
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